Rule 36 (India): how it works and where it is recognized

Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.

What Rule 36 is

Origin and authorising body. India, under Rule 36 of the Drugs and Cosmetics Rules 1945. The authorising body for each individual case is the Central Drugs Standard Control Organization (CDSCO), Directorate General of Health Services, Ministry of Health and Family Welfare, acting under that jurisdiction's pharmacy or medicines legislation.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Legal basis. Rule 36 of the Drugs and Cosmetics Rules 1945 permits the import of a small quantity of a drug for personal use, subject to specific conditions: the drug is for the personal use of the importer and not for sale or distribution, the quantity imported does not exceed a three-month supply for chronic conditions or such quantity as is necessary for the treatment of the patient for whom the drug is intended, the patient or the patient's treating physician submits a request to CDSCO, and the import is accompanied by a prescription from a registered medical practitioner.

Rule 36 is India's framework for personal-use import of unregistered medicines. It is among the most patient-friendly personal-import frameworks globally: it permits direct patient importation (with physician backing), it allows up to a three-month supply per import, and it has been used for decades by Indian patients accessing US-, EU-, and UK-registered medicines not available locally. The framework distinguishes Rule 36 personal import from commercial import (which requires a different licensing structure under the Drugs and Cosmetics Act).

CDSCO has issued multiple clarifying notifications confirming that Rule 36 imports do not require an Import Permit when the drug is for personal use and the quantity is reasonable for the prescribed treatment duration. Customs clearance at Indian ports of entry requires the prescription, the patient identification, and (for biologics or controlled substances) additional documentation. Indian patients commonly use Rule 36 for oncology agents, rare-disease biologics, dermatology specialty agents, and paediatric formulations not stocked locally. Major Indian customs ports handling specialty medicine imports include Delhi, Mumbai (CSIA), Chennai, Bengaluru, and Hyderabad.

This page consolidates Reserve Meds's operational view of the Rule 36 (India) framework across the ten destination countries where we currently coordinate cross-border supply. Earlier in our content build we maintained separate per-country sub-pages for each Rule 36 (India)-in-country combination; those sub-pages remain available for archival reference but are no longer separately indexed, and the operational intelligence they carried has been folded into the country-compatibility table below.

Reserved for you.

Who can use Rule 36

Rule 36 is used by Indian patients (or their treating physicians on their behalf) to import medicines for their personal use. The framework is patient-led rather than physician-led, although physician backing is required in the form of a prescription and clinical justification. The medicine must be for the personal use of the importing patient and cannot be redistributed or sold. Cross-border patients from outside India cannot use Rule 36; the framework is specifically for personal import by Indian residents.

In practical terms, a Reserve Meds case opens when the treating physician has identified the clinical need, has reached a decision to prescribe a specific medicine, and has determined that the locally available route is unsuitable or unavailable. We then layer the regulatory and supply-chain coordination on top of that clinical decision; we do not originate the prescribing question and we do not advise on the clinical choice. The decision sits with the physician throughout.

Drug categories typically covered under Rule 36

US- and EU-approved oncology agents not registered in India, rare-disease biologics (enzyme replacement therapies, gene therapies), dermatology specialty agents, paediatric formulations of adult-approved medicines, post-approval indications, and ophthalmology specialty agents.

The medicine itself must be source-country approved or in active regulatory development under a recognised reference authority (typically the US FDA, the European Medicines Agency, the UK MHRA, the Japan PMDA, or Health Canada). Most destination regulators will not authorise a Rule 36 (India) import for a medicine that lacks a recognised reference authorisation anywhere in the world, because the regulator's risk assessment leans on the source-country review as a substitute for its own.

Country compatibility

The table below summarises how the Rule 36 (India) framework is recognised across the ten destination countries where Reserve Meds currently coordinates cross-border supply. The "Accepts Rule 36 (India) dossiers" column reflects whether the destination regulator typically reviews and grants permits on the strength of a Rule 36 (India) clinical justification packet, or whether the patient must use a different parallel framework on the receiving side. Timelines reflect routine cases with a complete documentation set; first-import scenarios, paediatric weight-banded presentations, advanced therapy medicinal products, and large multi-cycle quantities can extend the regulator review by several weeks.

Notes. "Indirect" means the destination regulator does not directly accept Rule 36 (India) authorisation as the legal basis for import but does recognise a Rule 36 (India) authorisation as supporting precedent within its own named-patient or compassionate-use review. "Not applicable" means the framework is not a patient-access pathway in the cross-border sense and is shown here for completeness. Regulator names: NHRA (Bahrain), EDA (Egypt), CDSCO (India), JFDA (Jordan), KDFC (Kuwait), MoPH (Lebanon), MoH-DGPADC (Oman), MoPH-DPA (Qatar), SFDA (Saudi Arabia), and EDE (United Arab Emirates, federal from 29 December 2025).

Documentation required

A Rule 36 application is typically assembled in coordination with the treating physician, the dispensing facility, and the cross-border supply partner. The documentation set below covers the routine case; specific destination countries may require additional items (most frequently a hospital ethics committee notification for paediatric or complex cases, and an insurer pre-authorisation letter where the patient intends to seek reimbursement).

• Prescription from a registered medical practitioner in India.
• Patient identification (Aadhaar or passport).
• Clinical justification (typically a letter from the treating physician).
• Quantity calculation (up to three months for chronic conditions, or such quantity as is necessary for the prescribed treatment).
• For controlled substances or biologics: additional CDSCO documentation including NDPS Act compliance where applicable.
• Customs declaration at the port of entry.

Typical timeline

Customs clearance at Indian ports of entry: typically 3 to 10 business days for ambient small molecules, 5 to 14 business days for cold-chain biologics. End-to-end, most cases complete within 2 to 4 weeks. CDSCO does not pre-authorise routine Rule 36 imports, which significantly accelerates the timeline compared with permit-based jurisdictions. First-import scenarios or large quantities can trigger additional CDSCO scrutiny.

Costs and reimbursement

Drug cost is the US or EU acquisition cost plus international logistics, customs, dispensing handling (if any), and coordinator fees. Indian customs duties and GST apply (basic customs duty plus IGST; specialty medicines often qualify for concessional rates under the Customs Tariff Act). Insurer reimbursement is uncommon for personal imports; most Indian patients pay cash, though some private insurers reimburse selected oncology and rare-disease medicines.

Where Reserve Meds fits in

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine access. For Rule 36 (India) cases, we coordinate the US-side sourcing through a DSCSA-compliant specialty channel, prepare the documentation packet your physician submits, coordinate validated cold-chain logistics with continuous temperature logging into the destination country, and assign a single named coordinator through the case. We do not replace your treating physician, we do not replace the destination-country regulator, and we do not replace your dispensing pharmacy. We coordinate the supply side so the physician can focus on patient care.

For each of the ten destination countries above, we publish a country-specific page documenting the operational realities (which dispensing facilities handle named-patient cases, how the cold chain is verified at the local airport, how the dispensing pharmacy releases the medicine, and what the typical insurer interaction looks like). Those country pages, combined with this pathway page and the specific drug pages, give the prescribing physician and the patient a coherent picture of what to expect before any commitment is made.

Our concierge fee is itemised separately on every firm quote alongside the drug acquisition cost, international logistics, customs, and dispensing pharmacy handling. The patient sees the full breakdown before deciding to proceed; we do not bundle costs and we do not charge an intake deposit. If the case cannot proceed for regulatory or supply reasons, we say so before any payment is taken.

Next step

If your treating physician has identified a clinical need that fits the Rule 36 (India) framework and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your caseWhatsApp

Reserved for you.

---

Related

• All access pathways
• UAE access landscape
• Saudi Arabia: SFDA named-patient pathway
• When conventional access fails
• How Reserve Meds works